FDA Policy/General

Hahn Leading Harbinger Health Testing Startup

Former FDA commissioner Stephen Hahn has been named CEO of Flagship Pioneering’s new Harbinger Health startup. Flagship describes Harbinger as a bio-platform company pioneering the detection of early cancer with a simple blood test that combines artificial intelligence (AI) and machine learning advances with its recent discoveries about the biology of early cancer.

“By using this Bio-AI approach to identify cancer before it is visible or symptomatic, Harbinger Health’s proprietary HarbingerHx platform has the potential to create an entirely new paradigm for cancer diagnosis, enabling early therapeutic interventions or prevention,” the Flagship notice says.

Hahn joined Flagship earlier this year as chief medical officer of its Preemptive Medicine and Health Security Initiative.

Flagship says it has made an initial commitment of $50 million to Harbinger.

Hahn Leading Harbinger Health Testing Startup

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome